Genvoya Tablets / Film-coated
Cobicistat, Elvitegravir, Emtricitabine, Tenofovir
"150mg, 150mg, 200mg, 10mg"
GILEAD SCIENCES INTERNATIONAL LTD.
| Pack size | 30's HDPE Bottle |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | Modern Pharmaceutical Co. |
| Retail Price | 5549.00 AED |
Indications
Genvoya Tablets / Film-coated is used for:
COBICISTAT
Cobicistat is a cyp3a inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of hiv-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.
ELVITEGRAVIR
Elvitegravir in combination with an hiv protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults.
EMTRICITABINE
Indicated, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in adults and for postexposure prophylaxis of hiv infection in health care workers and others exposed occupationally or nonoccupationally via percutaneous injury or mucous membrane or nonintact skin contact with blood, tissues, or other body fluids associated with risk for transmission of the virus.
TENOFOVIR
Tenofovir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older.
Cobicistat is a cyp3a inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of hiv-1 infection. It is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of cobicistat is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir or tipranavir. Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain cobicistat interactions. Cobicistat and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications.
ELVITEGRAVIR
Elvitegravir in combination with an hiv protease inhibitor coadministered with ritonavir and with other antiretroviral drug(s) is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults.
EMTRICITABINE
Indicated, in combination with other antiretroviral agents, for the treatment of hiv-1 infection in adults and for postexposure prophylaxis of hiv infection in health care workers and others exposed occupationally or nonoccupationally via percutaneous injury or mucous membrane or nonintact skin contact with blood, tissues, or other body fluids associated with risk for transmission of the virus.
TENOFOVIR
Tenofovir is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older.
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Cobicistat, Elvitegravir, Emtricitabine, Tenofovir :
Mechanism of Action
COBICISTAT
Cobicistat is a mechanism-based inhibitor of cytochrome p450 3a (cyp3a) isoforms. Inhibition of cyp3a-mediated metabolism by cobicistat increases the systemic exposure of cyp3a substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-hiv activity on its own.
ELVITEGRAVIR
Elvitegravir is an hiv-1 integrase strand transfer inhibitor (insti). Integrase is an hiv-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of hiv-1 dna into host genomic dna, blocking the formation of the hiv-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases i or ii.
EMTRICITABINE
Emtricitabine works by inhibiting reverse transcriptase, the enzyme that copies hiv rna into new viral dna. Emtricitabine is a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which is responsible for the inhibition of hiv-1 reverse transcriptase. It competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into nascent viral dna, resulting in early chain termination. Therefore emtricitabine inhibits the activity of hiv-1 reverse transcriptase (rt) both by competing with the natural substrate deoxycytidine 5'-triphosphate and by its incorporation into viral dna. By inhibiting hiv-1 reverse transcriptase, emtricitabine can help to lower the amount of hiv, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called t cells or cd4+ t-cells). Both of these changes are associated with healthier immune systems and decreased likelihood of serious illness.
TENOFOVIR
Tenofovir inhibits the activity of hiv reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into dna, by dna chain termination. Specifically, the drugs are analogues of the naturally occurring deoxynucleotides needed to synthesize the viral dna and they compete with the natural deoxynucleotides for incorporation into the growing viral dna chain. However, unlike the natural deoxynucleotides substrates, nrtis and ntrtis (nucleoside/tide reverse transcriptase inhibitors) lack a 3'-hydroxyl group on the deoxyribose moiety. As a result, following incorporation of an nrti or an ntrti, the next incoming deoxynucleotide cannot form the next 5'-3' phosphodiester bond needed to extend the dna chain. Thus, when an nrti or ntrti is incorporated, viral dna synthesis is halted, a process known as chain termination. All nrtis and ntrtis are classified as competitive substrate inhibitors.
Cobicistat is a mechanism-based inhibitor of cytochrome p450 3a (cyp3a) isoforms. Inhibition of cyp3a-mediated metabolism by cobicistat increases the systemic exposure of cyp3a substrates atazanavir and darunavir and therefore enables increased anti-viral activity at a lower dosage. Cobicistat does not have any anti-hiv activity on its own.
ELVITEGRAVIR
Elvitegravir is an hiv-1 integrase strand transfer inhibitor (insti). Integrase is an hiv-1 encoded enzyme that is required for viral replication. Inhibition of integrase prevents the integration of hiv-1 dna into host genomic dna, blocking the formation of the hiv-1 provirus and propagation of the viral infection. Elvitegravir does not inhibit human topoisomerases i or ii.
EMTRICITABINE
Emtricitabine works by inhibiting reverse transcriptase, the enzyme that copies hiv rna into new viral dna. Emtricitabine is a synthetic nucleoside analogue of cytidine. It is phosphorylated by cellular enzymes to form emtricitabine 5'-triphosphate, which is responsible for the inhibition of hiv-1 reverse transcriptase. It competes with the natural substrate deoxycytidine 5'-triphosphate and incorporates into nascent viral dna, resulting in early chain termination. Therefore emtricitabine inhibits the activity of hiv-1 reverse transcriptase (rt) both by competing with the natural substrate deoxycytidine 5'-triphosphate and by its incorporation into viral dna. By inhibiting hiv-1 reverse transcriptase, emtricitabine can help to lower the amount of hiv, or "viral load", in a patient's body and can indirectly increase the number of immune system cells (called t cells or cd4+ t-cells). Both of these changes are associated with healthier immune systems and decreased likelihood of serious illness.
TENOFOVIR
Tenofovir inhibits the activity of hiv reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into dna, by dna chain termination. Specifically, the drugs are analogues of the naturally occurring deoxynucleotides needed to synthesize the viral dna and they compete with the natural deoxynucleotides for incorporation into the growing viral dna chain. However, unlike the natural deoxynucleotides substrates, nrtis and ntrtis (nucleoside/tide reverse transcriptase inhibitors) lack a 3'-hydroxyl group on the deoxyribose moiety. As a result, following incorporation of an nrti or an ntrti, the next incoming deoxynucleotide cannot form the next 5'-3' phosphodiester bond needed to extend the dna chain. Thus, when an nrti or ntrti is incorporated, viral dna synthesis is halted, a process known as chain termination. All nrtis and ntrtis are classified as competitive substrate inhibitors.
Note
Genvoya "150mg, 150mg, 200mg, 10mg" Tablets / Film-coated manufactured by GILEAD SCIENCES INTERNATIONAL LTD. . Its generic name is Cobicistat, Elvitegravir, Emtricitabine, Tenofovir. Genvoya is availble in United Arab Emirates.
Farmaco UAE drug index information on Genvoya Tablets / Film-coated is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.